Anne Li August 12th, 2017 anne2001.li@gmail.com
Three quarters of the drugs previously only accessible to patients via the Cancer Drugs Fund (CDF) are now approved on the NHS. The liver cancer drug sorafenib (Nexavar) has become the latest to be made available to some patients with advanced disease on the NHS in England following draft recommendations. 18 out of 24 treatments on the fund have now been reviewed and approved. Rose Gray, senior policy adviser at Cancer Research UK, said that the approvals made so far will mean that more patients will be able to access new and innovative treatments. Set up by the Government in 2010, the CDF was initially seen as a short-term solution to help pay for treatments deemed not cost effective for routine use on the NHS. But the cost of the drugs quickly saw the fund exceed its initial £200 million budget.
See original article at: https://www.cancerresearchuk.org/about-us/cancer-news/news-report/2017-08-11-3-in-4-cancer-drugs-fund-treatments-now-available-on-nhs
